Table 2 Patient Characteristics on Exacerbation During Japanese Cedar Pollen Season
|  | Exacerbation (+) | Exacerbation (−) |
|---|---|---|
No. patients | 41 | 75 |
Age, yr | 49.5 ± 2.9 | 46.5 ± 1.9 |
Sex, n (%) | Â | Â |
   Male | 16 (39.0) | 30 (40.0) |
   Female | 25 (61.0) | 45 (60.0) |
Type Atopic, n (%) | 31 (75.6) | 51 (68.0) |
   Nonatopic | 10 (24.4) | 24 (32.0) |
Duration of asthma, yr | 16.8 ± 2.2 | 15.2 ± 1.6 |
IgE RIST (U/mL) | 532.2 ± 101.1 | 542.7 ± 75.7 |
Cedar RAST (UA/mL) | 25.1 ± 5.5 | 22.4 ± 8.1 |
Histamine-PC20 (μg/mL) | 841 ± 288 (n = 15) | 1375 ± 886 (n = 29) |
Severity of asthma, n (%) | Â | Â |
   Mild | 6 (14.6) | 21 (28.0) |
   Moderate | 22 (53.7) | 39 (52.0) |
   Severe | 13 (31.7) | 15 (20.0) |
Therapy, n (%) | Â | Â |
   BDP | 34 (82.9) | 59 (78.7) |
   Slow-release theophylline | 37 (90.2) | 57 (76.0) |
   Oral β2-agonists | 21 (51.2) | 28 (37.3) |
Anti-allergic agents, n (%) | 5 (12.2) | 14 (18.7) |
Oral steroids, n (%) | 2 (4.9) | 4 (5.3) |